JBIO Jade Biosciences
Price Chart
Executive Summary
Jade Biosciences priced a public offering of 10 million shares at $15.00 per share, expecting gross proceeds of $150 million. The offering represents approximately 17% dilution based on the current market cap of $868M, and proceeds will fund clinical trials and R&D for its autoimmune pipeline.
Key Financial Metrics
Actionable Insight
The 17% dilution is material for a clinical-stage biotech with no approved products. Monitor for potential further dilution if the underwriters exercise the overallotment option. The stock may face near-term selling pressure as the market absorbs the new shares.
Key Facts
- Pricing of 10,000,000 shares at $15.00 per share for gross proceeds of $150 million
- Underwriters have a 30-day option to purchase up to an additional 1,500,000 shares
- Offering expected to close on June 5, 2026
- Proceeds to fund clinical trials, preclinical studies, manufacturing, and general corporate purposes
- Lead candidate JADE101 targets APRIL for IgA nephropathy; pipeline also includes JADE201 and JADE301
- Offering is being made under an effective shelf registration statement (Form S-3) declared effective May 15, 2026
Financial Impact
Dilution of approximately 17% based on current market cap of $868M; gross proceeds of $150M
Risk Factors
- Dilution of ~17% from the offering, with potential additional dilution from the underwriters' option
- Clinical-stage company with no approved products; pipeline risk for JADE101, JADE201, and JADE301
- Proceeds used for R&D with no near-term revenue expectation
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306490 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 4, 2026
today
|
8-K
| — | awaiting T+5 | — | — |
|
Jun 4, 2026
today
|
424B5
| — | awaiting T+5 | — | — |
|
Jun 4, 2026
1d ago
|
Press Release
| — | awaiting T+5 | — | — |
|
Jun 3, 2026
1d ago
|
424B5
| $17.62 awaiting T+5 | awaiting T+5 | — | $16.87 (+4.26%) |
|
Jun 3, 2026
1d ago
|
Press Release
| $17.62 awaiting T+5 | awaiting T+5 | — | $16.87 (+4.26%) |
|
Jun 1, 2026
4d ago
|
8-K
| $21.04 awaiting T+5 | awaiting T+5 | — | $16.87 (−19.82%) |
|
May 26, 2026
9d ago
|
Press Release
| $21.50 $17.75 | ▼ −17.44% | ▼ −18.65% | $16.87 (−21.53%) |
|
May 18, 2026
18d ago
|
EFFECT
| — | awaiting T+5 | — | — |
|
May 7, 2026
28d ago
|
S-3
| $25.81 $24.13 | ▲ +6.51% | ▲ +7.97% | $16.87 (+34.64%) |
|
May 7, 2026
28d ago
|
S-3
| $25.81 $24.13 | ▲ +6.51% | ▲ +7.97% | $16.87 (+34.64%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access